Cathay Biotech (688065.SS) Stock Price

Cathay Biotech Price

SSE·CLOSED
37.72
​
Market closed

Revenue has compounded at 15.1% per year over the past 9 years to 3.30 B CNY. Earnings per share have grown at 16.3% per year over the last 9 years. Cathay Biotech's net margin stands at 17.2%, down from 25.2% several years earlier. Cathay Biotech currently offers a dividend yield of about 1.06%. The payout ratio is around 50% of earnings. Analysts set a median price target of 66.20 CNY, implying 75.5% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Cathay Biotech stock price

Access this data via the Eulerpool API

Cathay Biotech business model & stock analysis

Cathay Biotech Inc. engages in the research and development, production and sales of new bio-based materials. The company is headquartered in Shanghai, Shanghai and currently employs 2,324 full-time employees. The company went IPO on 2020-08-12. The firm's primary products are biological long-chain dibasic acids and bio-based polyamide series, including lauric acid and brazilian acid, which are used in long-chain polyamides, fragrances, hot melt adhesives, lubricants, powder coatings and other areas. The firm sells its products to domestic and overseas markets.

Frequently asked questions about Cathay Biotech

Analysts currently set an average price target of 66.20 CNY for the Cathay Biotech stock (median: 66.20 CNY), implying +75.5 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Cathay Biotech stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cathay Biotech to generate revenue of 3.91 B CNY and earnings per share of 0.87 CNY.

Converted at the current exchange rate, the Cathay Biotech share trades at 5.02 EUR (37.72 CNY).

The Cathay Biotech share (688065.SS) is listed on 1 stock exchanges, including: Shanghai (688065.SS).

The expected revenue of Cathay Biotech is 3.91 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cathay Biotech is 614.11 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cathay Biotech is currently 43.51. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cathay Biotech stock.

The price-to-sales ratio (P/S) of Cathay Biotech is currently 6.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cathay Biotech stock.

The Eulerpool Quality Score for Cathay Biotech is 5/10.

The ISIN of Cathay Biotech is CNE100004447. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cathay Biotech is 688065.SS. The ticker symbol is used to trade Cathay Biotech shares on the stock exchange.

Fair ValueTerminal
36.21 CNY
Over-/UndervaluationTerminal
Fairly valued
Industry
Chemicals
Number of shares
Employees
Revenue per Employee
1.42 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Aug 12, 2020
ISIN
CNE100004447
Cusip
Y1R0FU109
Market capitalization
21.96 B CNYLarge Cap
52-Week Range
PEG
4.30
P/E ratio
P/Ee 2026
35.75
P/Ee 2027
29.88
P/Ee 2028
26.15
P/S
P/Se
6.83
EV/EBIT
34.57
P/B Ratio
1.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2.67 %
Dividend
Dividend yield
1.06 %
Est. Dividend Yield
1.19 %
Payout Ratio
50.09 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
5 years
Dividend not reduced since
2 years
Dividend increased since
2 years
Dividend withholding tax
10.00 %
Last updated Oct 8, 2026, 10:39 PM

Cathay Biotech Peer Group

Cathay Biotech Ticker

SHH · 688065.SS

Cathay Biotech FIGI

688065:CH · BBG00R2K8TZ3688065:CG · BBG00R2K8V33688065:C1 · BBG01FRBMGF5

All fundamentals and in-depth analysis of Cathay Biotech

Our stock analysis for Cathay Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cathay Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.